TITLE

Progressive multifocal leukoencephalopathy in autoimmune disorders

AUTHOR(S)
Focosi, D.; Maggi, F.; Ceccherini-Nelli, L.; Marchi, S.; Petrine, M.
PUB. DATE
April 2009
SOURCE
Gut;Apr2009, Vol. 58 Issue 4, p605
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the misconceptions on the article by Verbeek on JC viral loads as a predictor of progressive multifocal leukoencephalopathy (PML) in patients with Crohn's disease. It cites the author's statement saying that PML has been associated with immunosuppression as a consequence of organ transplantation and hematological malignancies. It adds that the author also interpret JC viruria in a seronegative gastrointestinal control as evidence of primo-infection.
ACCESSION #
45646924

 

Related Articles

  • Pre-Existing T- and B-Cell Defects in One Progressive Multifocal Leukoencephalopathy Patient. Sottini, Alessandra; Capra, Ruggero; Zanotti, Cinzia; Chiarini, Marco; Serana, Federico; Ricotta, Doris; Caimi, Luigi; Imberti, Luisa // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Progressive multifocal leukoencephalopathy (PML) usually occurs in patients with severe immunosuppression, hematological malignancies, chronic inflammatory conditions or receiving organ transplant. Recently, PML has also been observed in patients treated with monoclonal antibodies. By taking...

  • Pre-Existing T- and B-Cell Defects in One Progressive Multifocal Leukoencephalopathy Patient. Sottini, Alessandra; Capra, Ruggero; Zanotti, Cinzia; Chiarini, Marco; Serana, Federico; Ricotta, Doris; Caimi, Luigi; Imberti, Luisa // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Progressive multifocal leukoencephalopathy (PML) usually occurs in patients with severe immunosuppression, hematological malignancies, chronic inflammatory conditions or receiving organ transplant. Recently, PML has also been observed in patients treated with monoclonal antibodies. By taking...

  • Immunosuppressants/methotrexate.  // Reactions Weekly;8/18/2012, Issue 1415, p25 

    The article describes the case of an elderly woman who developed progressive multifocal leukoencephalopathy after taking immunosuppressants and methotrexate.

  • Progressive Multifocal Leukoencephalopathy and Newer Biological Agents. Berger, J. R. // Drug Safety;2010, Vol. 33 Issue 11, p969 

    Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the brain due to a polyoma virus, JC virus. Despite the ubiquity of this virus, PML is rare and almost always seen in association with an underlying immunosuppressive condition. In the last 30 years, AIDS has...

  • Progressive Multifocal Leukoencephalopathy in Transplant Patients. Safdieh, Joseph E. // Neurology Alert;Nov2011, Vol. 30 Issue 3, p19 

    Progressive Multifocal Leukoencephalopathy (PML) is Pa rare viral infection of the central nervous system that affects immunosuppressed patients. PML is caused by viral invasion of oligodendrocytes by the JC virus, leading to progressive multifocal demyelination. PML can occur in patients with...

  • In the Literature. Deresinski, Stan // Clinical Infectious Diseases;2/1/2012, Vol. 54 Issue 3, following p311 

    The article focuses on the survival rate of AIDS patients after progressive multifocal leukoencephalopathy (PML) and discusses the effects of organ transplantation and Natalizumab on PML. Combination antiretroviral therapy (CART) has replaced PML and also helped in decreasing the fatality rate...

  • Risk of Progressive Multifocal Leukoencephalopathy in Patients Treated with Natalizumab. Lichtenstein, Gary R. // Gastroenterology & Hepatology;Nov2012, Vol. 8 Issue 11, special section p6 

    The article discusses the risk facing patients treated with natalizumab concerning progressive multifocal leukoencephalopathy (PML). There are several factors associated with such risk including the presence of anti-JCV antibodies, prior treatment with an immunosuppressant, and the long duration...

  • Review on PML Risk Stratification in Natalizumab-Treated Multiple Sclerosis Patients. GRIGORIADIS, Nikolaos C. // Archives of Neuropsychiatry / Noropsikiatri Arsivi;Dec2011 Supplement, Vol. 48, p61 

    Natalizumab (NAB) is the first approved among the monoclonal antibodies tested for the treatment of relapsing forms of multiple sclerosis (MS). However, despite the high effectiveness of this drug in MS, the risk of JCV infection within the central nervous system (CNS) leading to progressive...

  • Predicting Risk of Progressive Multifocal Leukoencephalopathy from Natalizumab. Ropper, Allan H. // New England Journal of Medicine;5/17/2012, Vol. 366 Issue 20, p1938 

    The article discusses a study which examined the risk of progressive multifocal leukoencephalopathy (PML), by Bloomgren and colleagues, published within the issue. Study authors analyzed duration of drug use, additional immunosuppression and serologic status for JC virus in predicting the risk...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics